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Platelet  factor  4 (PF4), which is released by platelets 
during coagulation, binds very tightly to negatively 
charged oligosaccharides such as heparin. To date,  six 
other  proteins are known that  are homologous in se- 
quence with PF4 but  have  quite  different functions. 
The structure of a  tetramer of bovine PF4 complexed 
yith one Ni(CN);-  molecule has been determined at 3.0 
A resolution and  refined  to an R factor of 0.28. The 
current model contains  residues 24-85, no solvent, and 
one overall  temperature factor. Residues 1-13, which 
carried  an oligosaccharide chain,  were removed with 
elastase  to induce crystallization; residues 14-23  and 
presumably 86-88 are disordered  in  the  electron den- 
sity map. Because  no heavy atom derivative  was iso- 
morphous with  the  native  crystals,  the complex of PF4 
with one Ni(CN):- molecule was solved using a single, 
highly isomorphous Pt(CN)z- derivative  and  the itera- 
tive, single isomorphous replacement method. 
The secondary structure of the  PF4 subunit, from 
amino- to carboxyl-terminal end, consists of an ex- 
tended loop, three  strands of antiparallel @-sheet ar- 
ranged in a Greek key,  and one a-helix. The  tetramer 
contains two extended, six-stranded @-sheets, each 
formed by two  subunits, which are  arranged back-to- 
back to form a “@-bilayer” structure with  two  buried 
salt  bridges sandwiched in  the middle. The  carboxyl- 
terminal a-helices, which contain lysine residues that 
are thought to be intimately involved in binding hep- 
arin,  are  arranged  as  antiparallel  pairs on the  surface 
of each extended @-sheet. 
Platelet factor 4  (PF4)l is carried within the  a-granules of 
platelets in the form  on a noncovalent complex with a proteo- 
glycan carrier (Barber et al., 1972). PF4 is a  tetramer (Bock 
et al., 1980) of four identical polypeptide chains, each of which 
contains 88 residues (Mr = 9580) in the bovine molecule 
(Ciaglowski et al., 1986) or 70 residues in the human (Deuel 
et al., 1977; Hermodson et al., 1977; Morgan et al., 1977;  Walz 
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The abbreviations used are: PF4, platelet factor 4; AT-111, anti- 
thrombin III; HLA-A2, human class I histocompatibility antigen form 
A2; ISIR, iterative single isomorphous replacement; p-TG, P-throm- 
boglobulin. 
et al., 1977). The human and bovine sequences are 73% 
identical. 
When released into  the plasma from activated platelets, 
PF4  attracts white blood cells, i.e. neutrophils  and monocytes, 
and  its release may  be the signal that initiates inflammation 
(Deuel et al., 1981). Other possible functions of PF4 derive 
from its  strong binding to negatively charged polysaccharides, 
especially heparan  and heparin, for which it has a dissociation 
constant of 10-7.5 (Loscalzo et al., 1985). The ability of PF4 
to neutralize heparin and related polymers is of general inter- 
est because heparin has been shown to interact with over 50 
enzymes (Machovich, 1984), to suppress smooth muscle 
growth (Castellot et al., 1982), and  to accelerate angiogenesis 
in solid tumors  (Taylor  and Folkman, 1982). PF4  has recently 
been patented as “Oncostatin A for its ability to inhibit 
tumor growth (Twardzik and Todaro, 1987). It also has been 
shown to reverse immunosuppression in mice (Katz et al., 
1986). 
Platelet factor 4 also binds tightly and preferentially to 
double-stranded DNA in vitro.’ This binding probably does 
not occur in vivo, but  it might be an important  attribute of 
several recently discovered, growth-related proteins that  are 
homologous to PF4. Members of this class are 1) induced by 
y-interferon (Luster et al., 1985), 2) constitutively overex- 
pressed in transformed Chinese hamster  and  human cell lines 
(Anisowicz et al., 1987), 3) strongly induced by Rous sarcoma 
virus in fibroblast cell lines (Sugano et al., 1987; Bedard et al., 
1987), and 4) overexpressed in stimulated leukocytes (Schmid 
and Weissmann, 1987; Walz et al., 1987; Yoshimura et al., 
1987). 
Another homolog of PF4  that has been known for some 
time in the human platelet system is P-thromboglobulin and 
its two precursors, platelet basic protein  (Holt et al., 1986) 
and low affinity platelet factor 4 (Rucinski et al., 1979), which 
is also named connective tissue activating protein I11 (Castor 
et al., 1983). Collectively, these  proteins appear to be involved 
in inflammation and wound healing (Senior et al., 1983). 
When released by activated platelets during coagulation, 
PF4 displaces thrombin from the heparan on the surface of 
endothelial cells,  where thrombin is anticoagulant through its 
accelerated interactions with antithrombin I11 (AT-III), 
thrombomodulin, and protein C, into solution, where throm- 
bin is procoagulant through its interactions with fibrinogen 
and  other clotting factors  (Stern et al., 1985;  Loscalzo et a/., 
1985). It also prevents the formation of the ternary complexes 
between heparin, AT-111, and various procoagulant serine 
proteases that are intermediate in the heparin-accelerated 
inhibition of proteases by AT-I11 (Rosenberg and Damus, 
1973; Laurent et al., 1978). 
The strongest binding between heparin and  PF4 requires 
heparin molecules above 10,000 daltons in size or approxi- 
* P. Johnson, personal communication. 
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mately 16 saccharide units (Luscombe and Holbrook, 1983; 
Denton et al., 1983). Luscombe and Holbrook (1983) postu- 
lated that  the critical size arises from the heparin winding 
around the outside of a globular protein core. From small 
angle neutron  scattering experiments (Ibel et al., 1986), they 
were able to calculate a radius of 2.11 nm for the  PF4 core 
and an average radius of 2.5 nm for the heparin coiled around 
the core. 
A similar model has also been developed from x-ray diffrac- 
tion data by Cowan et al. (1986). They used the packing 
density of human  PF4  crystals  (Kurachi, 1978; Machin and 
Isaacs, 1984) and  a  rotation  function confirming 222 symme- 
try  in  the  PF4  tetramer  to deduce a model in which the  PF4 
core, represented as four tetrahedrally arranged spheres of 
radius 1.6 nm, had an overall radius of 3.6 nm. Using this 
method, they proposed that a 16-saccharide heparin coil with 
a radius of 1.7 nm could reach all four heparin binding sites 
on the PF4  tetramer. Although these models are undoubtedly 
correct in their overall concepts, they are based on very 
limited structural information. In $his paper we present a 
refined model of bovine PF4 at 3.0 A resolution. 
MATERIALS AND METHODS 
Preparation of PF4 Crystals-Platelet factor 4 was purified from 
bovine platelets as described by Ciaglowski et al. (1981); it was 
crystallized in space group P212121 with a = 63.7 A, b = 66.7 A, c = 
described by St. Charles et al. (1984) with the modification that  the 
80.5  A, and a tetramer of 32,000 daltons  in the asymmetric unit, as 
protein was treated with porcine elastase prior to crystallization. 
After the initial  report was published, we discovered that  the first 13 
amino acids, which included an oligosaccharide, must be removed 
from the amino-terminal  end of bovine PF4 before it will crystallize. 
An endogenous, contaminating protease removed these residues in 
our original crystallizations; however, we have found that porcine 
elastase will also catalyze the conversion with the advantage that  it 
is faster and more controllable. 
On this basis, PF4 could be reproducibly crystallized as follows. A 
10-20 mg/ml solution of PF4  in 50 mM Tris, pH 8.0,  was prepared 
and treated with porcine elastase (1:1000, w/w) for 0.5 h at 25 “C. 
The insoluble suspension was spun at 1200 X g for 30 s and the 
resulting oily pellet washed with several volumes of cold, 50 mM Tris 
buffer, pH 8.0. The pellet was dissolved in enough 0.4 M NaC1, 50 
mM Tris-HC1, pH 8.0, to give a final protein  concentration of 10 mg/ 
ml. This solution was set up in a hanging drop or nested dish 
arrangement (5-20 ql)  and allowed to vapor-equilibrate against 0.02- 
0.14 M NaCl. Crystals 0.5 X 0.5 X 1.0 mm in size  were obtained within 
1-2 weeks. They were stored in a stabilizing buffer of 20 mM Tris, 
pH 8.0. 
Data Collection-Diffraction data were collected to 3.0 A resolution 
on two crystals for both the nickel and platinum derivatives (Table 
I).  The intensities were measured on a Nicolet/Syntex P2, four circle 
TABLE I 
Diffraction data 




Nickel merged 10-3.0  7096  6912  0.044
Platinum 1 10-3.6 4098  39860.040  0.2
Platinum 2 3.8-3.0 3671  4 4  0.036  0. 8 
Platinum merged 10-3.0  7080 6901 0.047 
10-3.6 4103 4028 0.051 0.15 
3.8-3.0 3653 3454 0.039 0.16 
“Nickel” is elastase-treated bovine PF4 reacted with K2Ni(CN)r; 
Total relections possible within the resolution limits. 
“platinum”  is  elastase-treated bovine PF4 reacted with K2Pt(CN),. 
e Number of reflections with an intensity greater than twice the 
standard deviation. 
dRBym = I I Fi I - I F k  I I /,E I F; I summed over all sym- 
metry equivalent pairs of reflections L and k. 
e Rmr, = I I; - <I>k I /x 1 <I>, I summed over all i data sets 
for all k reflections used. <I>k is the average intensity  for reflection 
k. 
diffractometer, which had been  modified  for protein data collection 
with an extended detector arm and a 385-mm-long, helium-filled 
beam tunnel. The w scan of the reflection, which  was taken over 0.33” 
at 0.66”/min, was broken into 11 steps, of which the best seven were 
kept for the intensity measurement. The nickel-filtered, copper K, x- 
rays were generated at 40 kV, 25  mA. Crystals were mounted in glass 
capillaries with the long axis of the crystal, which  was parallel to  the 
crystallographic a-axis, aligned along the spindle axis. 
The intensity data were processed using the PROTSYS package 
of crystallographic programs implemented on a VAX 11/780 com- 
puter. Individual backgrounds were not collected. Instead, an empir- 
ical correction was calculated as a function of 20 and d, (Krieger et 
al., 1974). This approach saves significant time in the  data collection 
and gives R,, values for protein data  that are equal or  better than 
those from the traditional method. Radiation damage was corrected 
from a  linear  least squares analysis of four monitor reflections. The 
absorption correction was calculated by the method of North  et al. 
(1968) from measurements on two strong axial reflections (hOO) 
collected over a 180” range in d, in 15” increments. 
For each derivative, the  data were collected from 10 to 3.6 and 3.8 
to 3.0 8, on two crystals. Scaling and merging of the partial data sets 
was done with the DIFCOR program in the ROCKS suite of crystal- 
lographic programs (Reeke, 1984) using the overlapping 3.6-3.8 A 
data together with 10-2.9 A Okl data which were also collected on 
each crystal. 
Determination of the Phases-An exhaustive search for heavy atom 
derivatives, over a period of 2 years, failed to identify any heavy atom 
reagents that would produce site-specific derivatives isomorphous 
with the native crystals. Crystals of PF4 were found to be quite fragile 
and susceptible to cracking upon exposure to submillimolar concen- 
trations of heavy atom salts. However, potassium platinum tetra- 
cyanide (K2Pt(CN),-3H2O) generated an excellent, albeit nonisomor- 
phous derivative, as evidenced by a regular fracture pattern in the 
crystals, by precession photographs showing a larger unit cell, and by 
the retention of the high angle intensities. The  unit cell axes a, b, 
and c were, respectively, 0.16,  1.45, and 0.25 A longer than those of 
the native crystals. These observations offered the possibility that a 
light atom analog could  be used to prepare parent crystals isomor- 
phous with the platinum derivative. An isomorphous parent “deriva- 
tive” was prepared by treating native crystals with the chemically 
analogous complex, potassium nickel tetracyanide (KZNi(CN),). In 
both cases, derivatization was accomplished by  slow diffusion of the 
complex over a 2-day period. The crystals were placed in 200  pl of 
stabilizing buffer in  a microdialysis cell and floated on  top of 5 ml of 
stabilizing buffer containing 0.2 mM reagent. The dialysis cell was 
prepared from a 1.5-ml Eppendorf centrifuge tube. The center was 
removed from the cap, the tube below the upper rim was cut off, and 
dialysis membrane was then clamped between the cap and the rim. 
Patterson maps based on the differences in diffraction intensities 
and anomalous scattering between platinum and nickel derivatives 
indicated a single site of substitution. It was used to calculate initial 
phases for the nickel derivative as  the “native” from the equations 
for single isomorphous replacement. These phases were then refined 
by the iterative method of Wang (1985). 
Electron Density Fitting-The main chain of the four monomers 
in the crystallographic asymmetric unit were fit independently. Then 
the noncrystallographic symmetry transformation between the mon- 
omer with the best overall electron density (monomer A) and the 
other  three  subunits were calculated by least squares methods from 
the positions of equivalent mainchain C, atoms. Side chains for 
monomer A were then fit into the density. Since the monomers 
appeared to be very similar, we rotated and translated the completed 
A-monomer into  the density for the other  three monomers. No  major 
adjustments in the side chains of the other monomers were necessary 
before refinement  started. During refinement we examined regions 
that had  a questionable fit with 2F0 - F, electron density maps. As a 
final check of the model, we stepped through the  entire sequence of 
the tetramer in 24 consecutive “fragment-deleted maps. The segment 
in question, usually 11 residues, was removed from the model, five 
cycles of restrained  least  squares (Hendrickson and Konnert, 1980) 
were run, and  then a 2F, - F, electron density map was calculated. 
Refinement-The model was refined by restrained least squares 
(Hendrickson and Konnert, 1980) in two stages. In the first stage the 
restraints were chosen to make the four subunits equivalent, residues 
75-85 an ideal helix, and  the torsion angle x 3  of the cystines equal to * 90”.  The weighting factors were those recommended by Hendrick- 
son (1985). In the second stage the subunits were independent, 
residues 75-85 were partially constrained to be helical, and the 
2094 Structure of Bovine Platelet Factor 4 
cystines were as in stage 1. Due to the modest resolution of the 
diffraction data, individual  temperature  factors  and  solvent  were  not 
included. 
RESULTS 
The mean fractional isomorphous difference was 13.2% 
between the nickel and  platinum data sets. Fig. 1 shows the 
Harker  sections  from  the  isomorphous difference Patterson 
map calculated using I FR - F N ~  I as coefficients in the 
synthesis.  The single, well defined peak  indicated  one major 
binding site with fractional coordinates 0.064, 0.024, and 
0.229, respectively,  for x ,  y, and z. Early  electron  density  maps 
phased  with  this  solution were left-handed so the  coordinates 
were inverted for subsequent calculations. This  site was also 
observed in  an  anomalous difference Patterson  synthesis  us- 
ing anomalous difference data measured on  the  K2Pt(CN)4 
derivative (data  not  shown).  The occupancy and  positional 
parameters of the single  heavy atom  site were refined  by  full- 
matrix  least squares. The  final R factor, using 10-3.0 A data 
and  simple difference data, was 0.54 after 12 cycles of refine- 
ment. 
The  mean figure of merit of the  initial, single isomorphous 
replacement  phase  set was 0.34. The  phases were refined by 
the  iterative single isomorphous  replacement (ISIR) method 
(Wang, 1985).  A solvent  mask wa! prepared from the  starting 
SIR phases  using  all  data  to 3.0 A. This  mask was then used 
for electron  density  filtering  and  phase  refinement  for four 
cycles. A second mask was calculated based on  the  refined 
0 
FIG. 1. Patterson maps calculated from the intensity differ- 
ences between the nickel and platinum data sets. The three 
Harker  sections for space group P212121 (a) U = 0.5, (b )  V = 0.5, and 
( c )  W = 0.5 are shown with the first contour line representing 20% 
of the origin peak and each succeeding contour line representing an 
increment of 10%. Data between 10 and 4.2 A were used in the 
calculation. 
FIG. 2. ISIR electron density map of the amino terminus. 
The starting model for refinement of residues Cys-25 to  Asn-35 is 
superimposed on the electron  density map that was calculated at 3.0 
A resolution from the nickel  derivative data and the ISIR phases. 
a 
FIG. 3. Final fragment-deleted electron density map of the 
amino terminus. Residues Gln-24 to  Asn-35 from the refined model 
of PF4 (R  = 0.28) are superimposed on a 2F. - F, electron  density 
map. The map was calculated after five cycles of restrained least 
squares refinement that did not include Gln-24 to Ile-34. 
phases  and  the original SIR  phases were refined using the 
second mask. After calculating a third solvent mask from 
these  phases,  the original phases were subjected to  eight cycles 
of phase  refinement  resulting  in a final  mean figure of merit 
of 0.78. In effect, the 32,000-dalton PF4  structure was phased 
using a single, 50-electron heavy atom derivative. 
In the original ISIR-phased map, we fit residues 25-85 of 
all four subunits by first  fitting  the well defined, main  chain 
electron  density  in  all four subunits.  Transformation  matrices 
among  the  subunits were calculated by least  squares  super- 
position of these individually fit pieces of main chain. We 
then fit the side chains and entire main chain in the A- 
subunit.  Stretches of weaker electron  density  in  the A-sub- 
unit, which were primarily  in  the  amino-terminal region, were 
fit by  comparison with  equivalent  but  better defined  regions 
in  one or more of the  other  subunits. Fig. 2  shows our  initial 
model for the  amino  terminus region of subunit A superim- 
posed on the ISIR electron density. The amino-terminal 
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FIG. 4. Final  fragment-deleted electron density map of the 
carboxyl terminus. Residues Gln-70 to Gly-85 from the refined 
model of PF4 ( R  = 0.28) are superimposed on a 2F, - F, electron 
density map. The map  was calculated after five cycles of restrained 
least squares refinement that did not include the residues Tyr-75 to 
Gly-85. 
section had the weakest density in all four subunits. The 
complete A-subunit was then  rotated  into the electron density 
of the  other  three subunits using the transformation matices. 
After several false starts using the restrained least squares 
refinement program, we reduced the R factor from 0.49 to 
0.28 in 50  cycles with an error of 0.019 A in  the bond lengths. 
In  the early stages of the refinement we were able to locate 
Gln-24 in a 2F0 - F, electron density map. Fig. 3 shows the 
final model for the amino-terminal region displayed in Fig. 2. 
Fig. 4 shows the final model for the carboxyl-terminal region 
of subunit A. Fig. 5 shows the  entire C,-backbone of the AB 
dimer after refinement. Different views of the C,-backbone 
for all four subunits  plus the side chains of selected residues 
are shown in Figs. 6  and 7. The final electron density map 
contained density for 62 of the 75 residues present in the 
elastase-treated  PF4 (Asp-14 through Ser-88). No convincing 
electron density was seen for 10 residues on the amino- 
terminal end (Asp-14 through Gln-23) nor for the last 3 
residues on the carboxyl-terminal end. By contrast, the disul- 
fide bonds Cys-25 to Cys-51 and Cys-27 to Cys-67 were 
especially clear in the map. 
DISCUSSION 
For convenience in this discussion, we labeled as “A” the 
subunit that we fit in its entirety by manual methods, its 
partner in the extended @-sheet as “B,” its  nearest neighbor 
in  the opposite @-sheet  as “C,” and  its  farthest neighbor “D.” 
FIG. 5. The PF4 dimer. The a-car- 
bon backbone of residues 24-85 (subunit 
A) and residues 124-185 (subunit B) 
from the refined model  of PF4 are shown 
in stereo. The view is approximately 
down the AB noncrystallographic 2-fold 
axis. The positions of the C, atoms are 
marked with small circles. The two cys- 
tine bonds near the amino-terminal end 
of each subunit are  drawn with thin lines 
between the side chain atoms and large 
circles for the sulfur atoms. 
Residues 24-85 refer to monomer-A, which is used as the 
representative subunit of the  PF4 tetramer because it  inter- 
acts least with the nickel ion. Residues 124-185,224-285, and 
324-385 belong to subunits B, C, and D, respectively. Also, 
we have divided the  tetramer  into two nominal dimers con- 
sisting of the AB and CD monomers based on the presumed 
strength of the interactions among the subunits. There is no 
evidence for dimers existing independently in solution. 
The major elements of secondary structure in the PF4 
subunit, which are shown in stereo in Fig. 5  and  diagrammat- 
ically in Fig. 8, are  a 12-residue loop, three  strands of anti- 
parallel @-sheet,  and  a 12-residue helix. The helix, which is 
on the “outside” of the molecule, crosses the pleated sheet at 
an angle of approximately 52”. These elements place PF4 
among the a + @ class of protein  structures (Creighton, 1984). 
The four subunits in the crystallographic asymmetric unit  are 
paired to form two extended @-pleated sheets of six strands 
each (Fig. 5) which are  then arranged back-to-back (Fig. 6) 
to form a  tetramer. At  physiological  ionic strengths,  human 
PF4 exhibits the molecular weight characteristic of a  tetramer 
(Kaser-Glanzmann et al., 1972;  Bock et al., 1980). 
The PF4  tetramer in this p s t a l  structure  has approximate 
+mensions of 35 x 35 X 45 A and  a radius of gryation of  18.4 
A. Ibel et al. (1986) derived a value of 17.4 A from neutron 
scattering experiments. The difference is probably due to  a 
small expansion in the  PF4 structure caused by the nickel 
ion. The symmetry of the four subunits  is approximately 222, 
as expected, but  it is distorted by the binding of the nickel 
ion between tetramers. The tetramer is far from being pseudo- 
tetrahedral  as shown by the fact that  the putative heparin 
binding sites  are clearly grouped in pairs; the helices in the 
same dimer are  separated by approximately 14 A while* those 
in different dimers are  separated by approximately 36 A. The 
tetramer is packed along the b-axis in the crystal with the 
basic carboxyl-terminal helices of its subunits next to the 
acidic amino-terminal  ends of subunits in adjacent tetramers. 
The structure of PF4 is unusual. The most similar structure 
is that of the a1 and a2 domains of the class I histocompati- 
bility antigen, HLA-A2 (Bjorkman et al., 1987). However, 
HLA-A2 differs from PF4 dimer in having an eight-stranded 
@-sheet, longer helices, and  a greater separation between the 
helices. The widest separation between C, atoms of the two 
helices in HLA-A2 (1HLA jn  the Brookhaven Protein  Data 
Bank) is approximately 14 A, which is wide enoygh to bind  a 
peptide. The separation is approximately 10 A in PF4. In 
addition, the helices in HLA-A2 cross the @-sheet at  an angle 
of approximately -45” instead of the +52” found in PF4 
dimers. Despite these differences the related motifs of the two 
proteins are provocative given that  PF4 stimulates the im- 
mune system (Katz et al., 1986). Sheet  structures that extend 
across subunits also occur in dimers of prealbumin (Blake et 
al., 1974), concanavalin A (Reeke et al., 1975), alcohol dehy- 
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FIG. 6. The PF4 tetramer  with selected side chains. The  a-carbon backbone  from the refined  model of the 
PF4  tetramer  is  shown  in  stereo  as viewed approximately down the AC noncrystallographic 2-fold  axis. The AB 
dimer  is  drawn  with  darker lines. Side  chains for the residues involved in  the  internal  salt  bonds  (Glu-43  and Lys- 
65  in  each  monomer)  are shown as connected dots; for the four  lysines on  the  carboxyl-terminal helix  (Lys-76, -77, 
-80, -81 in each monomer)  the side chains  are shown as  line  segments. 
FIG. 7. The PF4 tetramer  and  the  nickel position. The  a-carbon backbone  from the refined model of the 
PF4 tetramer is shown in stereo, as viewed approximately down the AD noncrystallographic 2-fold axis. The 
position of Tyr-75  in  each  monomer  has been  labeled to identify the  monomers. Hollow circles mark  the  positions 
of the two  nickel atoms  that  are  shared  with  adjacent  tetramers.  Side  chains  are  drawn  as connected dots for the 
residues  involved in  the  internal  salt  bonds  (Glu-43  and  Lys-65  in  each  monomer). 
drogenase (Eklund  et al., 1976), and  aspartate  transcarbam- 
ylase R-chain  (Krause  et al., 1987). 
Secondary  Structure-Residues Glu-1 to  Leu-23 are miss- 
ing due to proteolytic removal and disorder. The first 13 
residues were removed with  elastase  prior  to  crystallization. 
The  other  10 missing residues are unobserved, possibly be- 
cause they include 5 acidic residues which repulse one  another 
so strongly in the low ionic strength environment of the 
crystals (20 mM Tris),  that  they locally denature  the  protein. 
We know that  the 10 residues are present because Edman 
sequencing of PF4 from a washed and redissolved crystal 
confirmed the  amino-terminal sequence from Asp-14 to  Gln- 
24. 
Residues Gln-24  to Ile-34 are  best described as being ran- 
dom coil or as forming  a  large, open loop. There  are  bends,  as 
defined by Kabsch  and  Sander (1983), centered at residues 25 
and 27 and  one hydrogen bond from Thr-31  to Cys-67 in  the 
&sheet (Fig. 8). The chain is also stabilized by the two 
disulfide bonds Cys-25 to  Cys-51  and Cys-27 to Cys-67. Res- 
idues  Asn-35 to  His-38 form an  external oop that is stabilized 
by a main chain hydrogen bond (38N + 350).  It does not 
reverse the  direction of the polypeptide chain  and could be 
viewed as a  single turn of helix. 
Residues  Ile-39 to Ser-46, which comprise strand I of the 
three-stranded  p-sheet  in  the  monomer, also form six main 
chain hydrogen bonds (Fig. 8) with the  adjacent monomer in 
the  extended  p-sheet. Leu-42 and Val-44 contact  the  hydro- 
phobic  surface of the  carboxyl-terminal helix. Glu-43 on  the 
“interior side” of the  &sheet  in monomer  A forms  an  internal 
salt bridge with Lys-265 of monomer C in the  other  extended 
@-sheet  and similarly for the  related  pair Glu-243/Lys-65. The 
respective Glu-OE1 to Lys-NZ  distances  are 2.77 and 3.22  A. 
The comparable salt bridges between monomers B and D, 
namely Glu-143/Lys-365 and Glu-343/Lys-16?, which have 
Glu-OE1  to  Lys-NZ  distances of 9.65 and 8.67 A, respectively, 
are  presumably  not made in  this  particular  crystal form due 
to  distortion by the nickel substitution. 
Residues Ala-47 to  Ser-53 form  a hairpin loop (Sibanda  and 
Thornton, 1985) between strands I and I1 of the /3-sheet. 
There  is  an  atypical  14-atom  turn i volving  a  hydrogen bond 
from Gly-48 to Cys-51. Residues Pro-54  to  Thr-59  and Arg- 
64 to  Leu-68 form strands I1 and 111, respectively, of the p- 
sheet. They  are  linked by residues Lys-60 to Gly-63, which 
form a hydrogen-bonded  reverse turn.  In  the  rat  (Doi et al., 
1987) and  human3 genes  for PF4,  an  intron  occurs between 
residues 57 and 58 in strand 11. There are two p-bulges 
(Richardson, 1981); a wide type a t  Ile-39/Ser-40  and a  G type 
at  Gly-63/Arg-64. 
Residues Gln-70  to Leu-74 loop between strand I11 and a 
helix at the  end of the molecule. There  is a  hydrogen bond 
between Gln-70 and Arg-72 which forms an  inverse  y-turn 
(Rose  et al., 1985).  Residues Tyr-75  to Gly-85 form an  a-helix 
that lies  diagonally across  the top of the @-sheet. Since  the 
axis of the helix follows the slope from  the  saddle  point of the 
sheet  rather  than  the rise, this  packing  arrangement falls into 
class  2 of Chou  et al. (1985) rather  than class 4. Although the 
former is less  favored  energetically in  theoretical  calculations, 
the difference is less  for antiparallel  @-sheets  than for parallel 
ones. 
The secondary structure  that we observe  for residues 24- 
85 of bovine PF4  differs significantly from  that  predicted by 
the Chou and Fasman algorithm (Lawler, 1981) for human 
PF4, which should  have  essentially  the  same ov rall structure 
as  the bovine protein,  We observe 18% a-helix, 29% p-sheet, 
19% reverse turn,  and 34% unordered coil, whereas  the  pre- 
M. Poncz,  personal  communication. 
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FIG. 8. Hydrogen  bonds  and topology of PF4. The four loops, 
three  strands of @-sheet,  and  one  a-helix  found  in  the PF4 monomer 
are  indicated  in a diagram of the topology of the monomer. The two 
cystine  bonds  are  shown  as shaded lines. The main  chain hydrogen 
bonds, as  determined by the  graphic display program  QUANTA,  are 
shown by arrows going from  the  donor  to  the acceptor. The criteria 
for a  hydrogen bond  are  that  the angles C=O. . .H, 0.  . .H-N,  and 
H-I-C be greater  than go”, and  that  the  distance  N. . O not exceed 
3.3 A for a “short” hydrogen bond  and 4.0 for a “long” one  (Baker 
and  Hubbard, 1984). A  hydrogen bond was included in  the  diagram 
if it was present  in  all four subunits  and was  a short  bond  in a t  least 
one of them.  Exceptions to  these  criteria  are  the  bonds S41 -+ T59 
and D84 -+ K80 which were long  in all the  subunits,  and R72 -+ Q70 
which  was short  in  subunits A and D but  absent  in  subunits B and 
C, which instead  had a  long  hydrogen bond  to D69. Several hydrogen 
bonds  within  the helix, namely K80 + K77, K81- 178, D84 -+ K80, 
and G85 -+ K81, which were short  in a t  least  one  subunit, were not 
included  because they were missing in  other  subunits. 
dicted structure is 55% a-helix, 18% @-sheet, 26% reverse 
turn,  and 1% unordered coil. The  predicted  structure  for  the 
large open loop is a strand of @-sheet  and a  reverse turn; for 
the  short,  external loop, another reverse turn; for strand I, 
helix; for strand 11, helix; for strand 111, @-sheet and helix; 
and  for  the  y-reverse  turn, helix. The reverse turns  at  residues 
47-50 and 61-63 are predicted correctly to  within a few 
residues, as is  the  carboxyl-terminal helix. Furthermore,  the 
prediction  that  the four  lysines implicated  in  binding  heparin 
would be clustered  on  one side of a helix is verified in  our 
structure. 
An exact  comparison between the  distribution of secondary 
structure  in  our model and  that  measured by circular  dichro- 
ism  on  human  PF4 (Villanueva et al., 1988), namely 15% a -  
helix, 25% @-structure,  and  60%  unordered coil, is  not possible 
because the  first 10 residues are disordered in our crystals. 
However, taken  at face  value, the  circular dichroism measure- 
ments imply that  these  10 residues are  neither  a-helix  nor @- 
sheet. 
Tertiary  and  Quaternary Interactions-Along with  the  in- 
trachain disulfide and hydrogen  bonds, there  are several  clus- 
ters of hydrophobic  residues  which contribute significantly to 
the  integrity of the monomer structure. Residues  Ile-34 and 
Pro-36 at the end of the random coil form a cluster with 
residues  Ile-39,  Ile-66, and  Leu-68 in the  6-sheet  and residues 
Leu-74 and Ile-78 in the  a-helix. At the helix-sheet interface 
residues Leu-42, Val-44, and Leu-56 in the 0-sheet are to- 
gether with residues Tyr-75, Leu-79, and Leu-83 in the  a-  
helix. 
The A/B dimer  is  maintained by six  hydrogen bonds (Fig. 
8) and by the  cluster of hydrophobic residues at the helix- 
sheet  interface which extends  into  the  adjacent monomer to 
include residues Leu-142, Val-144, Leu-156, Tyr-175, Leu- 
179, and Leu-183.  Only  3 of the 12  residues in  subunit B that 
are  within 3.5 8, of a residue in  subunit A are hydrophilic. 
The inner hydrophobic  surfaces of the a-helices actually 
overlap the  @-sheet  strands from the  adjacent monomer. A 
consequence of these  interactions is that  the shallow groove 
between the two helices, which has a  floor  defined by Leu-42, 
Val-44, Pro-54, Leu-56, and  the  equivalent residues in  subunit 
B,  and walls defined by residues  Gln-70, Tyr-75, Leu-79, Leu- 
83, and  the  equivalent residues in  subunit  B,  is  quite  hydro- 
phobic. 
Hydrophobic interactions  are  also  evident  at  the  interface 
of the  A/B  and  C/D dimers.  Residue Val-26 at  the  beginning 
of the long stretch of random coil and residues Ile-45 and 
Leu-57  in the  @-sheet  cluster  with  the  equivalent residues in 
subunit C. However, the  interface between the two dimers, 
which contains  the four buried  salt  links discussed  previously, 
appears to be predominantly hydrophilic. Sevcn of the 10 
residues in  subunits C and D that  are  within 3.5 A of a residue 
in  subunit A are hydrophilic. 
Additional  evidence  for the  structural significance of these 
interactions comes  from the  conservation of specific  residues 
in  the sequences of proteins  that  are homologous to  PF4. As 
shown in Fig. 9, the  salt link  between positions 43 and  65 is 
conserved  in the sequences of all  proteins homologous to  PF4 
with the sole exception of the  human  GRO  protein.  In  the 
Chinese  hamster  GRO  protein,  protein  9-E3,  and  protein 3- 
lOC, the acidic and basic  residues  have  switched positions  in 
the sequence. In  protein 3-10C, lysine is replaced by arginine 
a t  position 43. Also, in  almost  all  the homologs, hydrophobic 
residues occupy the same 12 positions identified above as 
having  important  structural roles in PF4. Hydrophilic resi- 
dues occur once at  position 66 and 74 and four times at 
position 83. 
Nickel Site-The structures of the four subunits in the 
crystallographic asymmetric  unit  are  quite similar; the largest 
root  mean  square  deviation between main  chain  coordinates 
is 0.69 A for subunits A and D. The tetramer, however, is 
significantly  asymmetric. Its  distortion from 222 symmetry in 
the structure reported here is caused by the Ni(CN2- ions, 
which insert between tetramers  along  the b-axis of the  crystals 
and  increase  the  axis by 1.45 A. The @-bilayer is pried  open 
along  the BD edge by approximately 5 8, measured between 
the amino termini of the two subunits. Four residues have 
non-carbon atoms within 6 A of the two nickel sites that 
bracket each tetramer, namely, Cys-325 and Gln-324 (N)  in 
subunit B and Lys-181 and Lys-177 in  subunit D. Lys-181, in 
particular, seems to  make a specific contact  (NZ  to  Ni  is 2.19 
A). Although the  tetramer, which occupies one asymmetric 
unit,  is  not  under a crystallographic constraint  to  have 222 
symmetry,  it is unlikely that  asymmetric  crystal  packing  alone 
could  cause the  substantial  distortions discussed above. 
Heparin  Binding Site-The  positively charged  amino acid 
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FIG. 9. Sequences of PF4 and its homologs. The sequences of bovine (Ciaglowski et al., 1986), human 
(Poncz et al., 1987), and  rat PF4 (Doi et al., 1987) are compared along with those of six homologous proteins, 
namely human 0-thromboglobulin (H-bTG Holt et al., 1986), y-interferon induced protein (IP-10; Luster et al., 
1985), Chinese hamster and human growth-related proteins (CHEF GRO, HUMN GRO; Anisowicz et aL, 1987), 
Rous sarcoma virus-induced protein (9-E3; Sugano et al., 1987), and mitogen-stimulated human leukocyte protein 
(3-IOC; Schmid and Weissmann, 1987). The positions are numbered according to  the bovine PF4 sequence with 
letters for insertions. Protein 9-E3 was also reported as pCHEF-4 with leucine replacing phenylalanine at  position 
5 (Bedard et al., 1987). Protein 3-1OC was also reported as neutrophil-activating factor by Walz et al. (1987) and 
monocyte-derived neutrophil chemotactic factor by Yoshimura et al. (1987). The alignments with the  PF4 sequence 
are taken from the original papers; residues identical with those in PF4 are  in boldface. The known or putative 
amino-terminal residue of the mature protein is boxed for each sequence. For human P-TG, the amino-terminal 
serine of platelet basic protein (Holt et al., 1986), the amino-terminal asparagine of  low affinity platelet factor 4 
(Rucinski et al., 1979) or connective tissue-activating protein I11 (Castor et nl., 1983) and  the amino-terminal 
glycine of P-TG (Begg et al., 1978) are indicated. Dots indicate exon-intron boundaries in the  rat (Doi et al., 1987) 
and  human3 PF4 genes. 
side chains, especially the cluster of four lysines (Lys-76, -77, 
-80, -81) near  the carboxyl-terminal end, are of paramount 
importance in binding heparin (Handin and Cohen, 1976). 
The refined positions of the four lysine side chains  are shown 
in Fig. 4  and 6. Lysine side chains, which are usually on the 
surface and highly mobile, are often disordered in crystal 
structures. In Fig.  4,  some electron density, albeit discontin- 
uous, is seen for all four lysine side chains. The side chain of 
Lys-81 is the best ordered of the four. The lysines are bunched 
on the side of the helix that is opposite to  the helix of the 
neighboring monomer (Fig. 6). Lawler (1981) showed that  the 
spacing of the four lysines in the  PF4 sequence would put 
them together on  one side of the helix that he had predicted 
for the carboxyl-terminal end of PF4. p-Thromboglobulin, a 
proteolyzed derivative of platelet basic protein, has  a lower 
affinity for heparin than does PF4. Lawler (1981) pointed out 
that  the extra residue (Gln-79a in Fig. 9) between the pairs 
of lysine residues in @-TG would create  a staggered rather 
than in-line  arrangement of the lysines. Our model of PF4 
predicts that one of the lysines in /3-TG, either 76 or 81, is 
buried between the carboxyl-terminal helix and  the @-sheet. 
To our  knowledge,  no other three-dimensional structure of 
a heparin-binding protein is known. In  a similar fashion to 
Lawler's analysis of the  PF4 sequence, Villaneuva (1984) has 
proposed a model of the heparin binding site in AT-I11 based 
on prediction of secondary structure  and chemical modifica- 
tion experiments. A helix containing lysines 282,286, and 299 
would  have the  three positive charges on the same side and 
optimally arranged to interact with three critical sulfates on 
the octasaccharide binding unit in heparin that is preferred 
In  the absence of a  structure of the heparin-PF4 complex, 
we can only speculate as  to how the complex might be formed. 
The negatively charged heparin has been shown to wrap 
around the outside of the  PF4 tetramer (Ibel et al., 1986) and 
to interact specifically with lysine residues. Handin  and 
Cohen (1976) showed that guanidination, which changes the 
structure  but  not the charge of the lysines, greatly reduced 
the binding of heparin while modifications to  the arginine 
residues had no effect. A preliminary analysis suggests two 
possible structures for the heparin complex. The polysaccha- 
ride chain could pass along the shallow hydrophobic groove 
between the two  helices of each dimer or it could cross-over 
the helices  more or less at right angles. The  latter route would 
follow a belt of positively charged residues around the  PF4 
tetramer. However, heparin binding to PF4, which is not  a 
very cationic protein (PI = 7.6; Handin and Cohen, 19761, 
need not be entirely electrostatic, as shown by related exper- 
iments on antithrombin. Although heparin binds specifically 
to lysine residues on antithrombin (Rosenberg and Damus, 
1973), the overall interaction is nonelectrostatic (Heuck et al., 
1985) and also involves  specific tryptophan residues in anti- 
by AT-111. 
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thrombin  (Einarsson  and Andersson, 1977; Villanueva et al., 
1980). 
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